Filing search / Iovance Biotherapeutics, Inc. / "Community"

8-K

EX-99.1

IOVA Iovance Biotherapeutics, Inc.

27 Feb 25

Iovance Biotherapeutics Reports Financial Results

4:05pm

. and globally. Our top commercial priorities are to drive broader adoption and utilization, increase patient referrals, add large community practices … adoption is on track to continue accelerating throughout 2025 with broader utilization, higher demand, and growth in community referrals. Iovance also

8-K

EX-99.1

IOVA Iovance Biotherapeutics, Inc.

7 Nov 24

Other Events

9:03pm

- Regimen Follow - Up & Return to Primary Oncologist TREATMENT ~34 DAYS Community Practice 13 © 2024, Iovance Biotherapeutics, Inc. Iovance Cell Therapy

8-K

EX-99.1

493r77pmhhq7k2

7 Nov 24

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

4:06pm

8-K

EX-99.1

ke6qwaorbj7ay8

8 Aug 24

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024

4:05pm

8-K

EX-99.1

7js4a8cxe wanhjtb

3 Jun 24

Other Events

8:01am

8-K

EX-99.1

8e09z6jf29c sq

29 Feb 24

Other Events

7:30am

8-K

EX-99.2

f1g46aevm9 7lo6rs

20 Feb 24

Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval

6:03am

8-K

EX-99.1

7ml38e12fukim

20 Feb 24

Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval

6:03am

8-K

EX-99.1

5gut es53cffed1t3du

26 Jan 24

Other Events

12:00am

8-K

EX-99.1

6kmvrfehhbccbn

8 Jan 24

Other Events

5:03pm

8-K

EX-99.1

r3kxiyj0c6gfgq13x0o

7 Nov 23

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023

4:05pm